B. Riley Analysts Boost Earnings Estimates for Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Investment analysts at B. Riley lifted their Q1 2024 earnings per share estimates for Perspective Therapeutics in a report released on Tuesday, April 9th. B. Riley analyst Y. Zhi now anticipates that the company will earn ($0.02) per share for the quarter, up from their prior estimate of ($0.03). B. Riley has a “Buy” rating and a $1.70 price target on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.10) per share. B. Riley also issued estimates for Perspective Therapeutics’ FY2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.09) EPS.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st.

Perspective Therapeutics Stock Up 3.5 %

NYSEAMERICAN:CATX opened at 1.47 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.07 and a current ratio of 1.07. Perspective Therapeutics has a 52 week low of 0.21 and a 52 week high of 1.60. The company has a market cap of $862.77 million, a price-to-earnings ratio of -14.70 and a beta of 1.56.

Insider Activity at Perspective Therapeutics

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares in the company, valued at 110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The shares were bought at an average cost of 0.95 per share, for a total transaction of 57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares in the company, valued at 110,934,724.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Markus Puhlmann purchased 280,000 shares of the stock in a transaction dated Wednesday, January 24th. The shares were purchased at an average price of 0.50 per share, for a total transaction of 140,000.00. Following the completion of the transaction, the insider now owns 1,375,425 shares in the company, valued at approximately 687,712.50. The disclosure for this purchase can be found here. Insiders have acquired a total of 60,758,439 shares of company stock worth $57,576,503 in the last three months. 5.72% of the stock is owned by company insiders.

Institutional Investors Weigh In On Perspective Therapeutics

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Perspective Therapeutics by 3.1% during the 4th quarter. Vanguard Group Inc. now owns 13,213,750 shares of the company’s stock worth $5,312,000 after acquiring an additional 395,124 shares in the last quarter. Taylor & Morgan Wealth Management LLC boosted its stake in shares of Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after acquiring an additional 50,000 shares in the last quarter. Creative Planning bought a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $35,000. HighTower Advisors LLC bought a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $314,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $32,000. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.